In cancer research, we often study systems separately. We look at tumor genetics, or we focus on the immune system, or we analyze epigenetic regulation. Each of these areas has produced important discoveries. But in recent years, it has become clear to me that some of the most meaningful progress happens when we study how these systems interact.

One of the most exciting areas today is the connection between epigenetics and the immune system. This relationship, which we call the epigenetic-immune axis, helps explain why some cancers respond to immunotherapy while others do not. It also opens new possibilities for combining treatments in smarter ways.

Why Immunotherapy Does Not Work for Everyone

Immunotherapy has transformed cancer care for many patients. Drugs that activate the immune system, such as checkpoint inhibitors, have shown remarkable success in cancers like melanoma and lung cancer. These therapies help the immune system recognize and attack tumor cells.

However, in breast cancer and several other cancers, the response to immunotherapy has been more limited. Some tumors are described as “cold,” meaning they do not attract or activate immune cells effectively. Others actively suppress immune activity, creating a protective environment that allows cancer cells to survive.

This raises an important question: why does the immune system fail to recognize some tumors?

The answer is not only genetic. It is also epigenetic.

How Epigenetics Controls Immune Visibility

Epigenetic mechanisms control which genes are turned on or off in a cell. This includes genes involved in immune recognition. For example, cancer cells may silence genes that produce proteins needed for immune detection, such as antigen presentation molecules.

If these genes are turned off, the immune system has a harder time identifying cancer cells as abnormal. The tumor becomes less visible, even if it carries many mutations.

In my own research on breast cancer, I have studied how epigenetic regulators influence gene expression programs that define cell identity. These same regulatory systems can also affect how cancer cells interact with the immune system. When key genes are silenced through DNA methylation or chromatin changes, the tumor may escape immune surveillance.

This is one reason why immunotherapy alone may not be enough. The immune system cannot attack what it cannot see.

Reversing Silence to Restore Recognition

One promising strategy is to use epigenetic therapies to reverse this silencing. Drugs that target DNA methylation or histone modifications can reactivate genes that were previously turned off.

When this happens, cancer cells may begin to express proteins that signal their presence to the immune system. They may also produce molecules that attract immune cells into the tumor environment.

This process can effectively turn a “cold” tumor into a “hot” one. Once the tumor becomes visible, immunotherapy has a better chance of working.

In this way, epigenetic therapy does not replace immunotherapy. It prepares the tumor for immune attack.

Combining Therapies for Greater Impact

The idea of combining epigenetic therapy with immunotherapy is gaining strong interest. Each approach addresses a different part of the problem.

• Epigenetic therapy helps restore gene expression and immune visibility
• Immunotherapy helps activate and sustain the immune response

Together, they may produce a stronger and more durable effect.

For example, a patient might receive a DNA methylation inhibitor to reactivate silenced immune-related genes. This could be followed by a checkpoint inhibitor that enables T cells to attack the tumor more effectively. Early studies suggest that this combination can improve response rates in certain cancers.

The timing and sequence of these treatments are also important. We must understand when to introduce each therapy to achieve the best outcome. This is an area where more research is needed.

Overcoming Resistance Through Integration

Resistance remains one of the biggest challenges in cancer treatment. Tumors often adapt to therapy, whether it is chemotherapy, hormone therapy, or immunotherapy.

Epigenetic changes are a key driver of this adaptation. They allow cancer cells to quickly adjust gene expression in response to stress. This flexibility helps tumors survive.

By targeting epigenetic mechanisms, we may be able to limit this adaptability. At the same time, activating the immune system creates additional pressure on the tumor.

The combination of these approaches may reduce the likelihood that cancer cells can escape. Instead of giving the tumor multiple opportunities to adapt, we create a more coordinated and sustained attack.

The Role of the Tumor Microenvironment

The epigenetic-immune axis also extends beyond cancer cells themselves. The tumor microenvironment plays an important role in shaping immune activity.

Fibroblasts, immune cells, and extracellular signals can all influence how epigenetic changes affect the tumor. Some signals may promote immune suppression, while others may support immune activation.

Understanding these interactions is essential for designing effective combination therapies. It is not enough to target the cancer cell alone. We must consider the entire system in which it exists.

Moving Toward Personalized Strategies

Not all patients will respond to the same combination of therapies. This is why personalization is so important.

By analyzing epigenetic patterns and immune profiles, we can begin to identify which patients are most likely to benefit from combined approaches. Some tumors may have strong epigenetic silencing of immune genes. Others may already have active immune environments but need additional support.

In the future, I believe we will use integrated biomarkers to guide treatment decisions. These markers will reflect both epigenetic status and immune activity, allowing us to design therapies that are tailored to each patient.

Teaching the Next Generation to Think Across Systems

As a mentor, I encourage my students to think beyond single pathways. The epigenetic-immune axis is a clear example of why this is necessary. Cancer is not controlled by one mechanism. It is shaped by multiple systems that interact with each other.

Students must learn to connect these systems. They must understand how changes in gene regulation affect immune behavior, how therapy influences both, and how the tumor adapts in response.

This kind of thinking prepares them to contribute to the next generation of cancer therapies.

A New Direction in Cancer Treatment

The intersection of epigenetics and immunology represents a powerful new direction in cancer research. By combining therapies that restore gene expression with those that activate the immune system, we can approach cancer from multiple angles at once.

This strategy is still developing, but it holds great promise. It reminds us that cancer is not just a genetic disease. It is a disease of regulation, interaction, and adaptation.

By understanding and targeting these layers together, we move closer to treatments that are not only more effective, but also more durable.

The post The Epigenetic-Immune Axis: A New Frontier for Combination Cancer Therapies appeared first on Chun Ju Chang.

When biology meets policy, we can turn research into action. We can shape smarter screening programs, guide more effective treatment guidelines, and build health systems that reflect the latest knowledge in cancer science. This connection is essential if we want our work to truly improve lives.

What the Estrogen Receptor Teaches Us About Resistance

In my research on breast cancer, one of the key areas of focus is endocrine resistance. Many breast tumors are initially sensitive to hormone therapy because they express the estrogen receptor, or ER. But over time, some of these tumors lose ER expression and stop responding to treatment. We have found that this loss can be caused by epigenetic silencing of the ESR1 gene, not by mutation or deletion.

This discovery matters not just for researchers but for clinicians and policy makers. If we can predict which patients are likely to lose ER expression, we can avoid ineffective treatments and move toward alternatives sooner. It also means that screening protocols, which often rely on receptor status at diagnosis, need to account for how that status may evolve during treatment.

Policies that support repeat biopsies, biomarker monitoring, and dynamic treatment planning could help tailor care more accurately, save costs, and reduce side effects for patients who would not benefit from standard hormone therapies.

Taiwan’s Health System as a Model for Integration

In Taiwan, we are fortunate to have a national healthcare system that collects comprehensive patient data and provides broad access to care. This system allows researchers and public health officials to work together more easily than in many other countries.

For example, the National Health Insurance Research Database contains decades of anonymized patient data that researchers can use to study cancer trends, treatment outcomes, and the long-term effectiveness of different therapies. When paired with molecular studies and clinical trials, this kind of data allows us to ask questions like: Which subtypes of breast cancer respond best to certain drug combinations? How does treatment timing affect survival? When should screening begin for women with specific genetic profiles?

In Taiwan, this level of integration has already improved screening programs for liver and cervical cancer, and I believe breast cancer can follow the same path, especially with more input from molecular biologists and epigenetic researchers.

Screening Must Keep Up With Science

Cancer screening programs have saved many lives by catching disease early, but they must evolve as we learn more about how cancers behave at the molecular level. A one-size-fits-all approach may no longer be sufficient. If national screening programs begin to incorporate molecular profiling, we could identify high-risk patients even when tumors are not yet visible. We could also reduce unnecessary biopsies and surgeries by distinguishing between aggressive and indolent tumors more accurately.

These improvements require not only scientific evidence but also policy changes. Governments must be willing to invest in new technologies, update clinical guidelines, and train healthcare workers to interpret more complex results. That means researchers like me must do a better job of communicating our findings in ways that policy makers can understand and apply.

Bridging the Gap Between Science and Systems

At China Medical University, we work closely with clinicians to explore how cancer biology research can inform healthcare decision-making. We share our findings with medical societies, and these conversations help ensure that scientific advances do not stay trapped in journals but make their way into hospitals and government offices.

I also encourage my students to think beyond the lab. I ask them to imagine how their experiments could influence treatment options, insurance coverage, or national prevention programs. When they see themselves not only as researchers but as contributors to public health, their work becomes more grounded and more impactful.

The Role of Translational Research in Public Policy

Translational research is about more than moving discoveries into drugs. It also means translating basic science into policy-relevant insights. For example, if we identify a subgroup of patients who benefit from a shorter course of therapy, that information should lead to updated treatment guidelines. If we discover a non-invasive biomarker that predicts tumor recurrence, health systems should consider incorporating it into follow-up care protocols.

This kind of translation does not happen automatically. It requires collaboration between research labs, hospitals, insurance providers, regulatory agencies, and ministries of health. It also requires researchers to think strategically about how their work can be measured, replicated, and scaled.

Moving Forward Together

As we learn more about how cancer behaves at the molecular level, we have a responsibility to make sure this knowledge shapes real-world care. In Taiwan, we have the infrastructure and talent to lead this kind of integration— we can not only treat disease more effectively but also build a smarter, more equitable system for everyone.

The post Research Should Not End at the Lab Bench appeared first on Chun Ju Chang.

For many students, especially those writing in a second language like English, the idea of publishing can feel overwhelming. My role as a mentor is to guide them through it with patience, structure, and shared purpose.

Starting With the Story

The first lesson I share with students is this: every good paper is about telling a compelling story. Your figures are not just charts, they are chapters. Your data is not just numbers, it is evidence. Before writing anything, I ask students to step back and explain the story of their research out loud. What question were you trying to answer? What did you find? Why does it matter?

Once they can explain that in plain language, we begin outlining the manuscript. I encourage them to see the Introduction as the “why,” the Methods as the “how,” the Results as the “what”. This structure helps students organize their thoughts and see that a paper is not a format, it is a logical flow of ideas.

Writing in English, Thinking in Science

For many of my students in Taiwan, English is a second language. This adds another layer of challenge to writing for international journals. But I remind them that science has its own language. Clarity, not complexity, is the goal.

I show them examples of well-written abstracts and help them practice writing short summaries of their work. We revise these summaries many times. This practice builds confidence and helps students become more comfortable with expressing scientific ideas in English.

I also encourage students to read actively. When they read papers from top journals, I ask them to notice how authors present their data, structure their conclusions that are supported by the figures. Reading with purpose helps them develop their own voice as writers.

Navigating Peer Review and Rejection

After submitting a manuscript, the peer review process begins. For first-time authors, this can be a shock. Reviews are often blunt, sometimes critical, and occasionally hard to interpret. I guide my students through the reviewer comments line by line. We discuss what is fair, what needs clarification, and how to respond constructively.

Most papers are not accepted on the first try. One of my previous students had a paper rejected with a long list of reviewer comments. But we revised the manuscript carefully and resubmitted it to another journal. It was accepted, and the student learned that resilience is part of being a scientist.

Teaching Ethical Authorship

In our lab, we follow clear authorship guidelines based on contributions to the project. I involve students in discussions about authorship and in what order. I also show them how to cite sources correctly, and keep good research records.

I want my students to see themselves as responsible members of the research community.

Learning Through Co-Writing

One of the most effective methods I use is co-writing. I ask them to write a draft and I revise through each section. Then we review on feedback and edits together, and ask questions that push them to think more deeply about their analysis.

This back-and-forth process teaches them how to revise, defend their ideas, and strengthen their arguments. Over time, students begin to take more ownership of the writing and become more confident in their ability to communicate their research.

Presenting the Paper, Not Just Publishing It

I often ask students to present their work in seminars. This helps them reflect on what they learned, how the project evolved, and how to explain their findings clearly. It also prepares them for conference talks, thesis defenses, and future collaborations.

These experiences not only strengthen their resumes but also shape their core skillsets as scientists.

Mentorship That Lasts Beyond the Paper

Publishing a paper is a proud moment, but for me, the most meaningful part is watching a student grow into a thoughtful, ethical, and capable researcher. I stay in touch with many former students who now lead labs of their own or work in academia. They tell me they still use the mentoring approaches they learned during the graduate training.

That is the real power of academic publishing, not just the paper, but the person it helps shape.

The post Why Publishing Is More Than a Requirement appeared first on Chun Ju Chang.

The Teacher Development Center and Faculty Growth

At CMU the Faculty Development Center plays a central role in supporting faculty. The Center’s mission is to elevate teaching quality, foster lifelong learning for faculty and promote a learning environment where teaching and research advance together. Through programs like new‑faculty orientation, teaching workshops, peer professional communities and faculty mentor-mentee meetings, the Center helps create a robust support system for academic staff.

New Faculty Onboarding

The Faculty Development Center provides downloadable documents and resources for new faculty orientation. This kind of structure helps align individual faculty goals with institutional priorities, and it enables mentoring, clearer career planning and accountability. Faculty professional communities self‑organize to share teaching practices, research insights and challenges

Integrating AI and Technology into Teaching Practice

One of the most exciting areas at CMU is how we’re integrating advanced teaching technologies into the classroom. We’ve adopted AI‑enabled teaching environments, cloud‑based teaching tools and virtual desktop solutions in computer classrooms to respond to evolving teaching needs. The university offers workshops on how to use generative AI in teaching, how to design digitally‑enhanced lessons and how to create interactive classrooms. As a researcher I believe this is critical. When faculty use innovative tools and teaching methods it not only benefits our students but also stimulates faculty to think differently about how research and teaching connect.

Aligning Teaching with Research Ambitions

In my own role as a professor and researcher, I emphasize that faculty should not treat teaching as a burden separate from research. Instead I encourage them to view teaching as an opportunity to refine their research questions, integrate latest findings into the classroom and engage students in research‑informed learning. When faculty teach with current research examples, students benefit, faculty sharpen their concepts, and both teaching and research advance together.

Mentoring Faculty to Mentor Students

One of my passions is mentoring junior faculty so they become strong mentors themselves. I guide them in how to supervise students, how to integrate research projects into teaching labs, how to publish with students and how to build international collaborations. This cascades down so that our students benefit from a culture where teaching, research, mentorship and global engagement are interwoven.

Global Engagement, Faculty and Student Development

We strive to foster Faculty development including international teaching and research exposure. We have bilingual and English‑medium instruction training workshops for faculty to enhance their global teaching competence. By encouraging faculty to think globally, bring international perspectives into their teaching, and engage students in research collaborations abroad, we create a globally‑aware research‑teaching ecosystem.

My Personal Commitment and Vision

As someone who trained abroad and returned to Taiwan, I feel a strong responsibility to shape an academic culture where faculty thrive in research and teaching, where students gain from both, and where institutional systems support excellence and innovation. I strive to model this by conducting translational research, teaching across disciplines, mentoring junior faculty and contributing to faculty development programs. My hope is that CMU becomes a place where faculty feel empowered to innovate in research, explore new teaching methods and guide the next generation of scientists.

The post Fostering Faculty Excellence as a Researcher‑Educator appeared first on Chun Ju Chang.

When I reflect on the journey of training young scientists here in Taiwan, I see one key ingredient: helping students think globally from day one. At China Medical University (CMU) we believe in preparing life science talent not just for local impact but for a world stage. This means giving students access to international research, cross‑border mentorship, English‑language communication and the openness to learn and share across cultures.

International Exchanges That Open Doors

One of the most exciting initiatives at CMU is our student exchange and internship programs. Through the Office of Global Affairs we support student participation in overseas internships, summer schools and dual‐degree programs. For example, our exchange students have gone to partner universities in Japan,Singapore, the United States and Australia. These experiences immerse students in different research environments, expose them to diverse teaching methods and build their confidence in international teamwork.

I always tell students: when you present your research in English in another country, you’re not just talking science, you’re showing that you belong in the global conversation. At CMU we subsidize students to go abroad and bring that perspective back to Taiwan. 

Research Competitions and English Communication

Another pillar in our talent‐building strategy is helping students build communication skills and research confidence. We run internal research competitions, thesis training in English, and workshops on presentation skills. My focus as a mentor has often been to encourage students to write and present in English even if they are more comfortable in Chinese, because the best science needs to be discussed without borders.

By emphasizing English proficiency and good science storytelling we help our graduates publish internationally, collaborate internationally and lead labs or biotech teams anywhere in the world. This culture of performance and communication is critical for bridging Taiwan’s research system and the global life science ecosystem.

Mentorship That Connects across Borders

From my own experience, studying at UCLA and doing postdoctoral work at MD Anderson Cancer Center, I know how mentorship, exposure and collaboration shape scientific careers. At CMU I work to provide similar opportunities for our students and postdocs: pairing them with international visits, helping them present to international conferences, encouraging co-authorship and job opportunities with collaborators abroad.

I believe mentorship is more than research technique: it includes guiding young scientists in how to publish, how to form international networks, how to adapt to new research cultures. It also means helping students stay curious, resilient and open‑minded— qualities that make a true global scientist.

Building a Life Science Ecosystem in Taiwan

Cultivating global talent is not just about sending students abroad. It’s about building a robust ecosystem at home that supports international standards: bilingual courses, international faculty, joint research programs, modern labs and global partnerships. CMU has postgraduate programs in biomedical sciences, translational medicine, cancer biology and aging research that offer joint mentorship and training.

We also integrate student exchanges and mixed‐language courses so that our students learn alongside peers from around the world. For example our International Student Exchange Program (ISEP) invites overseas students to Taiwan and offers English‐language courses on Taiwanese health insurance, hospital management, integrative medicine and more. 

Why This Matters for Taiwan and the World

Why all this effort? Because the world needs more life science leaders who understand both local context and global trends. Taiwan has unique advantages: a high‑quality healthcare system, rich biomedical data, innovation capacity and strong student talent. By training scientists who are globally fluent, we amplify these strengths and contribute to global scientific progress.

From a broader perspective, when Taiwan’s scientists publish, collaborate and lead on the world stage, they help bring different perspectives to major challenges: cancer, aging, health systems, biotechnology. And by doing this, Taiwan moves from being a contributor to being a leader.

How Students Can Make the Most of It

To students reading this: if you aspire to be a globally‐minded life scientist, here are a few pieces of advice:

• Seek out international exposure: internships, exchange programs, symposiums.
  
• Build your English communication: publish in English, present in English, collaborate in English.
  
• Embrace mentorship: seek mentors inside and outside Taiwan who can support you.
  
• Be curious about global issues: health sciences, biotechnology trends, etc.
  
• Stay rooted locally: while expanding globally, know Taiwan’s strengths and how you can contribute back.
  

My Commitment as a Mentor

As a professor and mentor I am committed to creating pathways for students to grow, learn and lead. I strive to connect young scientists in Taiwan with collaborators in the U.S., Asia and Europe. I encourage our students to step outside comfort zones, engage with researchers around the world and bring back new knowledge to Taiwan. I believe that when we support the next generation with global opportunities and strong mentorship the impact is multiplied: students become researchers, innovators and leaders who serve both Taiwan and the world.

The post Empowering the Next Generation: How Taiwan Is Cultivating Global Life Science Talent appeared first on Chun Ju Chang.

One of the most exciting parts of being a cancer researcher is watching an idea that began in a lab eventually help a patient in the real world. This journey — from the laboratory “bench” to the patient’s “bedside” — is what we call translational research.

It’s where science meets medicine, where theory becomes therapy, and where hope becomes healing. Translational research is not just a buzzword — it’s a critical bridge that connects basic discovery with better care. I’ve been lucky to witness and participate in this process throughout my career, especially during my time MD Anderson Cancer Center, an institution that leads the way in turning research into reality.

Today, I’d like to share a few success stories that highlight just how powerful translational cancer research can be.

Case Study #1: Targeting HER2 in Breast Cancer

Years ago, breast cancer was largely treated the same way for every patient: surgery, chemotherapy, radiation. But thanks to basic science research, we now know that breast cancer is not one disease — it’s many. One of the most important discoveries came from studying a protein called HER2 (human epidermal growth factor receptor 2).

Researchers at found that about 20% of breast cancers had too much HER2, which made the cancer grow faster and spread more aggressively. This discovery led to the development of a targeted therapy: trastuzumab (Herceptin).

Herceptin was a game changer. It specifically targets HER2-positive tumors and leaves other cells alone, reducing side effects and significantly improving survival. This therapy is now a standard treatment around the world — and it all started with basic science in the lab.

Case Study #2: Immune Checkpoint Inhibitors

For decades, researchers dreamed of using the immune system to fight cancer. The idea was simple: if your immune system can fight off viruses and bacteria, why not tumors too?

At MD Anderson Cancer Center, scientists like Dr. Jim Allison helped bring that dream to life. He discovered a molecule called CTLA-4, which acts like a brake on immune cells. By developing a drug that blocks CTLA-4, researchers were able to “release the brake” and let immune cells attack tumors.

This led to the creation of immune checkpoint inhibitors, a revolutionary class of drugs now used to treat melanoma, lung cancer, kidney cancer, and more. What’s incredible is that some patients who were once given just months to live are now surviving for years — and in some cases, being cured.

Case Study #3: Liquid Biopsies for Early Detection

Another exciting breakthrough has been in the development of liquid biopsies — blood tests that can detect cancer-related DNA fragments before a tumor even shows symptoms.

At institutions like UCLA and China Medical University, researchers are working on these non-invasive tools to help with early detection, treatment monitoring, and even relapse prediction.

Imagine catching pancreatic cancer at Stage I instead of Stage IV. Or being able to tell if a treatment is working just by drawing blood instead of doing an invasive biopsy. That’s the future of oncology — and it’s being built right now, in labs around the world.

What Makes Translational Research Work?

Turning lab discoveries into patient treatments is not easy. It takes years of testing, clinical trials, regulatory approval, and often cross-disciplinary teamwork between scientists, doctors, statisticians, and patients themselves.

Here are a few ingredients that make translational research successful:

• Curiosity in the lab: Great translational work starts with asking the right questions and designing strong basic science experiments.
  
• Collaboration across fields: Researchers and clinicians must work hand-in-hand to identify which findings are most promising and relevant to patients.
  
• Patient participation: Clinical trials are essential, and they depend on the bravery of patients who are willing to try new treatments.
  
• Long-term support: These breakthroughs don’t happen overnight. They need sustained funding, mentoring, and infrastructure.
  

Lessons for the Next Generation

One of the most important messages I share with my students is this: Your research matters, even if it feels far from the clinic today. A protein you study now may become tomorrow’s biomarker. A pathway you map today may lead to a new drug in ten years.

It’s a long road, but a deeply meaningful one. I was proud of what it represented. That with enough care, rigor, and collaboration, our work can reach beyond the page and into the lives of real people.

From Hope to Healing

Cancer is a complex, evolving disease. But so is our science. Every step we take — every experiment, every trial, every breakthrough — brings us closer to more effective, more personalized, and more compassionate care.

Translational research is where hope becomes healing. It reminds us that research is not just about answers — it’s about impact.

And for all of us in the field, that’s the most meaningful success of all.

The post From Bench to Bedside: Translational Cancer Research Success Stories appeared first on Chun Ju Chang.

As the world’s population gets older, we are facing a new and urgent challenge in medicine: how do we best care for elderly cancer patients?

In my work as a cancer researcher and pharmacist, I’ve seen firsthand how age changes everything — from how cancer develops, to how patients respond to treatment, to how they want to live their final years. Geriatric oncology, the field focused on cancer in older adults, is more important now than ever before.

We are living longer, which is something to celebrate. But with that longevity comes a rise in age-related cancers. At the same time, elderly patients often have unique needs — they may have other chronic health issues, take multiple medications, or have limited mobility or support. These factors demand a more thoughtful, personalized approach to both treatment and end-of-life care.

Why “One-Size-Fits-All” Doesn’t Work

Traditional cancer treatments — surgery, chemotherapy, radiation — were often developed with younger, stronger patients in mind. But those same treatments can be risky or even harmful for someone who is 80 years old and living with heart disease or dementia.

This is where innovation is needed. The goal is not just to fight cancer, but to protect quality of life, respect patient values, and reduce suffering. That’s where geriatric oncology and palliative care intersect — and where I’ve chosen to focus much of my research and teaching.

New Tools for Assessing Elderly Patients

One exciting development is the rise of geriatric assessment tools in cancer care. These are checklists and evaluations that go beyond basic lab tests or imaging. They assess things like:

• Daily functioning (Can the patient cook? Bathe? Walk safely?)
  
• Cognitive health (Is there memory loss or confusion?)
  
• Emotional well-being
  
• Nutritional status
  
• Social support
  

By using these assessments early in treatment planning, doctors can better predict how a patient will respond to therapy and tailor recommendations accordingly. For example, a frail 90-year-old might skip aggressive chemotherapy in favor of a gentler approach that improves comfort and dignity — and avoids unnecessary hospitalizations.

Less Can Be More: De-Escalating Treatment

Another innovation in geriatric oncology is the concept of treatment de-escalation. Instead of giving the “maximum tolerated dose,” more physicians are considering what’s called the minimum effective dose — the lowest intensity of treatment that still works.

This can mean shorter courses of radiation, lower doses of chemotherapy, or even hormone-based therapies that slow cancer progression without harsh side effects. These tailored plans are especially useful for older patients who want to remain at home, maintain independence, or avoid long recovery times.

Importantly, research shows that many elderly patients prefer quality of life over quantity of time — but those conversations need to happen early and with compassion.

Palliative Care Is Not Giving Up — It’s a Medical Specialty

Too often, people think of palliative care as “the end,” but that’s a misunderstanding. Palliative care is active medical care that focuses on relieving pain, managing symptoms, and supporting emotional well-being — at any stage of a serious illness.

Palliative care teams include doctors, nurses, social workers, and chaplains. They work alongside oncologists to ensure that patients not only live longer, but live better.

In recent years, new innovations in palliative care include:

• Early integration with cancer treatment (not just at the end of life)
  
• Home-based palliative care options using telemedicine
  
• Palliative chemotherapy designed to shrink tumors and relieve pain without aiming for a cure
  
• Advanced care planning tools that help patients express their wishes for the future
  

These advances are helping patients and families feel more in control, more supported, and less alone.

Insights from the Field: Geriatric Leaders and Research Trends

I’ve had the honor of learning from some brilliant colleagues in this space that have shaped how we understand care for older adults.

On the research side, we are focusing on aging biology, polypharmacy (managing many medications), and cancer care models for rural and aging populations. Some are even exploring the molecular differences in how cancer grows in older versus younger patients, which could lead to age-specific treatments in the future.

I find this deeply hopeful. It means the next generation of scientists and doctors are paying attention to the aging population and asking the right questions.

Respecting the Whole Person

At the heart of all this innovation is a simple truth: our elderly patients are not just “old people with cancer.” They are parents, grandparents, teachers, musicians, farmers, and artists. They have lived full lives, and they deserve care that honors who they are — not just what disease they have.

That’s what drives me every day. Whether I’m working with a medical student or helping design a research study, I always ask: What would I want for my own mother or father?

Toward a Kinder, Smarter Future

The future of cancer care for aging populations is about balance — balancing science with empathy, treatment with comfort, and longevity with dignity.

We are making progress. With new tools, new models, and new mindsets, we can give our elderly patients more than just time — we can give them meaningful time, cared for with thoughtfulness and respect.

And that, to me, is one of the most important innovations of all.

The post Innovations in Geriatric Oncology and Palliative Care for Aging Populations appeared first on Chun Ju Chang.

When people think of a scientist, they often picture a man in a lab coat. But look a little closer — in cancer research labs, hospitals, and classrooms around the world, you’ll find brilliant, passionate women leading the charge against one of humanity’s toughest diseases.

As a woman in cancer science myself, I’ve seen how far we’ve come — and how far we still need to go. While more women are entering medical research than ever before, they are still underrepresented in leadership positions, major research grants, and high-profile speaking opportunities. It’s time for that to change.

My Journey as a Woman in Science

I grew up in Taiwan, where girls were often encouraged to pursue reassuring careers, such as teacher or government jobs. But I was lucky — my family supported my academic dreams, and I found role models early on who helped me believe that I could contribute to science in a meaningful way.

Earning my Ph.D. at UCLA and opened doors for me, but I still noticed the imbalance. In meetings, I was often the only woman in the room. In grant panels, my male colleagues were more likely to be recognized — even when we had the same qualifications.

Despite the challenges, I’ve been fortunate to work alongside other incredible women who inspire me every day. These women have not only advanced cancer science but have made it easier for those of us coming after them.

Women Who Inspire Me

There are countless women in oncology who deserve to be celebrated. Here are just a few who have shaped the field and inspired others like me:

• Dr. Mary-Claire King – A geneticist who discovered the BRCA1 gene mutation linked to breast cancer, changing how we screen and treat women at risk.
  
• Dr. Lori Wilson – A surgical oncologist and researcher who has spoken openly about her own cancer diagnosis, offering powerful insights on both patient care and resilience.
  
• Dr. Padmanee Sharma – A leader in immunotherapy research, she has made major strides in understanding how the immune system can be harnessed to fight cancer.
  

These women remind us that success in science is not just about individual brilliance — it’s about creating space for others, challenging norms, and speaking up when it matters.

The Challenges We Still Face

While progress has been made, gender equity in cancer research is far from complete. Here are just a few of the challenges women in science continue to face:

• The Leadership Gap: Women make up a large share of Ph.D. students and junior researchers, but are underrepresented in senior faculty roles, department chairs, and major research institutions.
  
• Grant Disparities: Studies have shown that women are less likely to receive large research grants or renewals, even when they have strong publication records.
  
• Work-Life Balance: Many women scientists still struggle with expectations around caregiving, which can limit career growth in a field that demands long hours and constant publishing.
  
• Implicit Bias: From how papers are reviewed to how speakers are selected for conferences, unconscious bias can affect visibility and recognition.
  

These are systemic issues — not personal failings — and they require systemic solutions.

The Power of Women in Cancer Research 

One organization that has made a huge impact in my life and the lives of many women in oncology is Women in Cancer Research (WICR), a group within the American Association for Cancer Research.

WICR provides a platform for networking, mentorship, and leadership development. They host panels, sponsor awards, and highlight the achievements of women in the field. But more than that, they help create a community — a place where women can share experiences, build confidence, and support one another.

With WICR’s support, I’ve mentored early-career scientists and also received support myself from women who have faced similar struggles. These connections make all the difference in a field that can sometimes feel isolating.

How We Can Move Forward

So how do we build a more equitable and inclusive future in cancer research?

Here are a few places to start:

• Mentorship: Senior scientists — both men and women — must take time to mentor and sponsor female researchers, helping them navigate funding, publishing, and leadership.
  
• Visibility: Conference organizers, journal editors, and institutions must be intentional about including women in keynote roles, review boards, and editorial positions.
  
• Policy Support: Universities and research centers need to offer better parental leave policies, flexible work arrangements, and support for caregivers.
  
• Bias Training: Everyone in the field should undergo training to recognize and reduce unconscious bias in hiring, evaluation, and collaboration.
  
• Celebrate Successes: Let’s shine a light on women who are doing groundbreaking work, not just during Women’s History Month, but year-round.
  

Lifting as We Climb

Science should be a place where ideas rise — not where people are held back. As women in cancer research, we bring not only scientific expertise but also empathy, collaboration, and determination.

I’m proud to stand on the shoulders of those who came before me — and I hope to be a steady hand for those climbing behind. Gender equity is not just a women’s issue — it’s a scientific one. Because when all voices are heard, we all benefit.

The post Gender Equity in Oncology: The Role of Women in Advancing Cancer Science appeared first on Chun Ju Chang.